Serum from a patient with Gushing's syndrome who was being treated with mitotane contained components that interfered with determination of cholesterol in the Du Pont aca.A measured concentration of cholesterol of 4.19 gIL in the undilutedserum increased to a calculated concentrationof 9.50 g/L in diluted serum. Adding additional cholesterol oxidase (EC 1.1.3.6) overcame the reactioninhibitionin the undilutedsample;addingadditionalcholesterolesterase(EC 3.1.1.13) had no effect. There is the potential for clinically significant underestimationof cholesterol withthe acain such patients, because the interference may remain undetected.
Materials and Methods
We diluted the patient's serum samples for the aca cholesterol method with de-iomzed water. We concurrently analyzed our patient's serum by a continuous-flow (SMA H; Technicon Instruments Corp., Tarrytown, NY) enzymatic method (with and without dilution), calculating results from absorbance because values for cholesterol exceeding 5 g/L are not printed out. We also compared results for lipemic serum samples from three other subjects (triglyceride 15-27 g/L, cholesterol 3.30-3.80 g/L), as analyzed with the aca, diluted and undiluted.
To prepare a sample with cholesterol and triglyceride content similar to that of our patient, we combined 0. Table 1 shows the effect of diluting the patient's sample before analysis with the aca. Unlike the aca, the SMA II gave similar results for the patient's serum whether diluted or undiluted (9.82 g/L for the undiluted sample and 10.14 g/L for the threefold diluted sample). To our surprise, we found no significant difference in measured cholesterol in lipemic samples from our three other control subjects, regardless of whether the samples were diluted before analysis with the aca.
Results

Cholesterol values by the manual nonenzymatic method
were similar for the patient's serum and /3-IL (9.70 and 9.50 g/L, respectively). When we recorded the absorbance changes of the aca reaction for the patient's serum and for human (3-lipoprotein, however, we found significant differences. The absorbance of the patient's serum continued to increase slowly during the 10-mm monitoring period, whereas the absorbance of human /3-lipoprotein increased rapidly and reached the endpoint (Figure 1) . Although the cholesterol content of the f3-lipoprotein we used in this part of the study was about half that of the patient's, the absorbance values were similar at the time at which the aca would measure and report the results of the reaction. The /3-IL specimen, which had a cholesterol content similar to our patient's serum (about 10.0 g/L), had an absorbance approximately twice that of the patient's serum, but also reached the endpoint quickly. Thus the slow reaction exhibited by the aca was limited to the samples from the mitotanetreated patient.
When we added additional CO and horseradish peroxidase from other aca packs, the cholesterol measured in our patient's sample increased (Table 2) , but adding more cholesterol esterase, in addition to CO and horseradish peroxidase, did not cause any further increase. Measured cholesterolinthe/3-LLspecimenwasnotaffectedbyaddingCO and horseradish peroxidase to the aca pack. Adding only 0.5 U of Pseudomonas CO to the aca pack resulted in a measured cholesterol in our patient's sample of 9.40 g/L;
greater amounts of this CO did not further increase the measured cholesterol.
To assess whether mitotane might inhibit the aca reaction we dissolved mitotane in alcohol, evaporated volumes containing 2.5 mg of mitotane in clean tubes, and added 0.5 mL of serum with known high cholesterol content (4.13-8.29 gIL). After mixing and incubating them for 1 h at 37 #{176}C, we 
Discussion
We initially thought that lipemia might be the cause of interference with the aca method, but other lipemic samples and our simulated /3-IL specimen did not show this effect. The latter specimen gave accurate results on the aca even though the cholesterol concentration exceeded the manufacturer's upper limit of linearity (8.00 g/L). Moreover, we found no interference with the SMAll enzymatic method or the manual nonenzymatic method. Our studies of absorbance showed that the aca reaction was progressing more slowly in the patient's samples and did not reach an endpoint (Figure 1) , which suggested that an inhibitor was responsible for the falsely low measured cholesterol in our patient. Indeed, adding more CO and horseradish peroxidase from other aca test packs or CO from another source overcame this problem. From our data, however, 0.5 U of CO from Dii Pont was not equivalent to 0.5 U of CO from Amano Pharmaceutical
Co. in reversing the inhibition of the CO with our patient's serum. Du Pont's CO is from
Nocardia erythropolis;
Amano's is from Pseudomonas. 
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(Technicon declined to divulge the bacterial source of the CO used in the SMA H cholesterol reagent.) We concluded that CO from Nocardia erythropolis was inhibited by the patient's serum but CO from Pseudomonas was not. Although we have not conclusively identified the interfering substance in the patient's serum, we believe that the history of treatment with mitotane is significant. In addition to its direct cytotoxic effect on mitochondria of the adrenal cortex, especially the zona fasciculata and zona reticularis (6), mitotane inhibits the activities of 11-hydroxylase and 18-hydroxylase (7) . However, our results indicate that in vitro addition of mitotane to serum did not affect the activity of cholesterol oxidase. We therefore suspect that the mechanism inthis patientwas related to the cytotoxic effect of mitotane, resulting in the abnormal release of steroids or steroid intermediates. To our knowledge, therehave been no previous reports describing lipid abnormalities of this magnitude in patients treated with mitotane.
Ed. Note: A spokesperson for Du Pont informs us that this interference will be noted in future product literature.
